RBC
AGTC

Roble Belko & Company’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Roble Belko & Company’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-200
Closed -$3K – 308
2016
Q1 		$3K Hold
200
– – ﹤0.01% 233
2015
Q4 		$4K Hold
200
– – ﹤0.01% 182
2015
Q3 		$3K Hold
200
– – ﹤0.01% 183
2015
Q2 		$3K Hold
200
– – ﹤0.01% 209
2015
Q1 		$4K Buy
+200
New +$4.47K ﹤0.01% 205

Other funds holding AGTC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Roble Belko & Company's AGTC Position: Q2 2016 in Review

Roble Belko & Company sold out of Applied Genetic Technologies Corporation (AGTC) in Q2 2016, closing a stake of 200 shares — an estimated $3K sold.

Roble Belko & Company first reported a position in AGTC in Q1 2015 and held it in 5 quarters. The position peaked at $4K in Q4 2015. 94 funds tracked by Wall St. Rank hold AGTC as of Q2 2016.

  • Roble Belko & Company reported no remaining Applied Genetic Technologies Corporation position as of Q2 2016 after selling out during the quarter.
  • Roble Belko & Company sold 200 Applied Genetic Technologies Corporation shares in Q2 2016, an estimated $3K.
  • Roble Belko & Company first reported a position in Applied Genetic Technologies Corporation in Q1 2015 and held it in 5 quarters.
  • Roble Belko & Company's Applied Genetic Technologies Corporation position peaked at $4K in Q4 2015.
  • 94 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q2 2016.

Based on Roble Belko & Company's 13F filing for Q2 2016, filed 11 Aug 2016.